[Rinsho ketsueki] The Japanese journal of clinical hematology最新文献_第6页

[Histiocytic sarcoma derived from the same origin as splenic marginal zone lymphoma revealed by exome analysis]. [通过外显子组分析发现与脾边缘区淋巴瘤同源的组织细胞肉瘤]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.737

Daiki Komata, Mutsumi Takahata, Yoshinori Makino, Takashi Ishio, Hiroshi Iwasaki, Shin Ichihara, Masumi Tsuda, Shinya Tanaka, Makoto Ibata

{"title":"[Histiocytic sarcoma derived from the same origin as splenic marginal zone lymphoma revealed by exome analysis].","authors":"Daiki Komata, Mutsumi Takahata, Yoshinori Makino, Takashi Ishio, Hiroshi Iwasaki, Shin Ichihara, Masumi Tsuda, Shinya Tanaka, Makoto Ibata","doi":"10.11406/rinketsu.65.737","DOIUrl":"https://doi.org/10.11406/rinketsu.65.737","url":null,"abstract":"Histiocytic sarcoma (HS) is a rare aggressive hematological malignancy reported to occur secondary to B cell lymphoma. We report a case of HS secondary to splenic marginal zone lymphoma (SMZL) complicated by autoimmune hemolytic anemia (AIHA) in a 64-year-old man. He was referred to our department with anemia and was diagnosed as having AIHA. After starting treatment with prednisolone, atypical lymphocytes appeared in his blood tests, and a bone marrow biopsy revealed invasion by B cell lymphoma. A CT scan showed splenomegaly and a pancreatic mass, which confirmed the diagnosis of SMZL. The patient received bendamustine and rituximab as chemotherapy, which rapidly improved the anemia and splenomegaly and reduced atypical lymphocytes. However, left lumbar back pain appeared along with an increase in the pancreatic mass, and he died suddenly of acute renal failure. An autopsy revealed that the tumor had invaded several organs including the pancreas, and immunohistochemistry was positive for CD163, leading to the diagnosis of HS. Furthermore, the specimens of SMZL and HS were positive for IgH gene reconstitution, and exome analysis showed genetic abnormalities in 226 genes including CARD11, suggesting that the SMZL and HS had the same origin.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"65 8","pages":"737-741"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Successful induction therapy for acute myeloid leukemia under management with extracorporeal membrane oxygenation]. [使用体外膜氧合技术成功诱导治疗急性髓性白血病]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.330

Yusuke Takaki, Toshiyuki Yanai, Tatsuhiro Shibata, Takehiro Honma, Maki Otsuka, Yoshitaka Yamasaki, Shuki Oya, Takayuki Nakamura, Yoshimi Maehiro, Maki Yamaguchi, Kazutoshi Aoyama, Fumihiko Mouri, Yoshihiro Fukumoto, Koji Nagafuji

{"title":"[Successful induction therapy for acute myeloid leukemia under management with extracorporeal membrane oxygenation].","authors":"Yusuke Takaki, Toshiyuki Yanai, Tatsuhiro Shibata, Takehiro Honma, Maki Otsuka, Yoshitaka Yamasaki, Shuki Oya, Takayuki Nakamura, Yoshimi Maehiro, Maki Yamaguchi, Kazutoshi Aoyama, Fumihiko Mouri, Yoshihiro Fukumoto, Koji Nagafuji","doi":"10.11406/rinketsu.65.330","DOIUrl":"10.11406/rinketsu.65.330","url":null,"abstract":"A 53-year-old woman presented with shortness of breath and hyperleukocytosis and was admitted to our hospital. Shortly after, she went into cardiopulmonary arrest and was resuscitated. Her white blood cell count was 566,000/µl, with 94.5% cup-like blasts positive for MPO staining and FLT3-ITD positive, so she was diagnosed with acute myeloid leukemia (AML) M1. She also had disseminated intravascular coagulation and tumor lysis syndrome. Extracorporeal membrane oxygenation (ECMO) was started to manage bilateral pulmonary thromboembolism that had developed due to deep vein thrombosis, and induction therapy was performed under ECMO. On the third day of illness, the patient developed cerebral hemorrhage. Hematological remission was confirmed on the 39th day of illness. After consolidation therapy with chemotherapy and an FLT3 inhibitor, she underwent allogeneic hematopoietic stem cell transplantation, and remains alive. Case reports suggest strong evidence of mortality benefit from ECMO in patients with hematologic malignancies, particularly when ECMO served as a bridge through chemotherapy. Our patient suffered from cardiopulmonary arrest due to hyperleukocytosis and pulmonary thromboembolism, but was saved by induction of remission under ECMO. Improvements in supportive care should lead to reduction in early deaths during induction therapy.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"65 5","pages":"330-334"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141201512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Chronic myeloid leukemia: 2024 update on novel therapeutic strategies]. [慢性髓性白血病：2024 年新型治疗策略更新]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.976

Yosuke Minami, Ryo Yoshimaru

引用次数: 0

[Diagnosis and management of POEMS syndrome]. [POEMS 综合征的诊断和管理]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.1033

Chikako Ohwada

引用次数: 0

[Molecular pathogenesis of adult T-cell leukemia/lymphoma]. [成人 T 细胞白血病/淋巴瘤的分子发病机制]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.1019

Junji Koya, Yasunori Kogure, Keisuke Kataoka

{"title":"[Molecular pathogenesis of adult T-cell leukemia/lymphoma].","authors":"Junji Koya, Yasunori Kogure, Keisuke Kataoka","doi":"10.11406/rinketsu.65.1019","DOIUrl":"10.11406/rinketsu.65.1019","url":null,"abstract":"Adult T-cell leukemia/lymphoma (ATLL) is an aggressive peripheral T-cell malignancy caused by human T-cell leukemia virus type-1 (HTLV-1) infection. Genetic alterations are thought to contribute to the pathogenesis of ATLL alongside HTLV-1 products such as Tax and HBZ. Several large-scale genetic analyses have delineated the entire landscape of somatic alterations in ATLL, which is characterized by frequent alterations in T-cell receptor/NF-κB pathways and immune-related molecules. Notably, up to one-fourth of ATLL patients harbor structural variations disrupting the 3'-UTR of the PD-L1 gene, which facilitate escape of tumor cells from anti-tumor immunity. Among these alterations, PRKCB and IRF4 mutations, PD-L1 amplification, and CDKN2A deletion are associated with poor prognosis in ATLL. More recently, several single-cell transcriptome and immune repertoire analyses have revealed phenotypic features of premalignant cells and tumor heterogeneity as well as virus- and tumor-related changes of the non-malignant hematopoietic pool in ATLL. Here we summarize the current understanding of the molecular pathogenesis of ATLL, focusing on recent progress made by genetic, epigenetic, and single-cell analyses. These findings not only provide a deeper understanding of the molecular pathobiology of ATLL, but also have significant implications for diagnostic and therapeutic strategies.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"65 9","pages":"1019-1024"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Recent advances in the treatment of DLBCL]. [治疗 DLBCL 的最新进展]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.995

Kana Miyazaki

引用次数: 0

[Thrombopoietin-mediated regulation of hematopoietic stem cells]. [血小板生成素介导的造血干细胞调节]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.872

Ayako Nakamura-Ishizu

引用次数: 0

[Future prospects for the development of novel agents for acute myeloid leukemia]. [开发治疗急性髓性白血病新型药物的未来前景]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.353

Naoko Hosono

引用次数: 0

[Current status and challenges of AML treatment with FLT3 inhibitors]. [FLT3抑制剂治疗急性髓细胞白血病的现状与挑战]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.684

Yuichi Ishikawa

{"title":"[Current status and challenges of AML treatment with FLT3 inhibitors].","authors":"Yuichi Ishikawa","doi":"10.11406/rinketsu.65.684","DOIUrl":"https://doi.org/10.11406/rinketsu.65.684","url":null,"abstract":"FLT3 mutation is one of the most frequent genetic mutations in AML, identified in approximately 30% of patients, and FLT3-ITD mutation is considered a poor prognostic factor. Based on these molecular and clinical backgrounds, FLT3 mutations are considered promising therapeutic targets in AML, and intensive development of targeted therapeutics has been ongoing for more than two decades. Recently, combination of FLT3 inhibitors with intensive chemotherapy for untreated AML patients with FLT3 mutations and FLT3 inhibitor monotherapy for relapsed/refractory patients have been approved. In Japan, the combination of quizartinib and intensive chemotherapy for untreated FLT3-ITD-positive AML was approved in 2023. Clinical use of FLT3 inhibitors shows strong promise for improving the clinical outcomes of these AML patients with an extremely poor prognosis. Meanwhile, various resistance mechanisms to FLT3 inhibitors have been identified, including the emergence of resistance-associated mutations, and attenuated inhibitory effects of FLT3 inhibitors involving the bone marrow microenvironment surrounding AML cells. Thus, future efforts should aim to optimize combination therapy based on the characteristics of each FLT3 inhibitor, develop biomarkers that could inform treatment selection, and to better understand these resistance mechanisms and develop methods for overcoming them.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"65 7","pages":"684-692"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141891238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Current state and future prospects of off-the-shelf allogeneic CAR NK therapy]. [现成的同种异体 CAR NK 疗法的现状和未来前景]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2024-01-01 DOI: 10.11406/rinketsu.65.668

Chihaya Imai

引用次数: 0